Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark.
The GLP-1 agonist failed to delay disease progression in patients in two …
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on
Aldeyra Therapeutics was hoping the third time would be the charm for its dry eye drug this St. Patrick’s Day. No such luck. The FDA
The biopharma industry is looking for creative ways to cushion the effect of the Trump administration’s “most favored nation” deals on US pricing. Two lawyers
Today we’re announcing two exciting editorial hires at Endpoints News: Karen Weintraub + Kevin Miller. Karen Weintraub is our new deputy editor and will help
Epic last week scored a win in a lawsuit that revolves around who has a right to patient health data. On Friday, the electronic health
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark.
The GLP-1 agonist failed to delay disease progression in patients in two …